Search Results
Apr 15, 2026, 14:12 ET Trojan Battery Unveils Lithium Solution for E-Z-GO RXV® Gen 1 ELiTE® Golf Carts
Trojan Battery Company has revolutionized deep-cycle battery technology by introducing generations of deep cycle flooded, lithium-ion, gel, AGM, and AES batteries.Based in Santa Fe Springs, California, Trojan Battery operates manufacturing facilities in Sandersville and Lithonia, Georgia; Santa
More news about: Trojan Battery
Apr 14, 2026, 15:40 ET Gray, Inc. Welcomes Two Distinguished Industry Leaders to Its Board of Directors
accomplished Board that includes Chairman Jim Gray; Aftab Shahsingh, Americas Head of Industrial Services, Morgan Stanley; Franklin Gray, Vice President, Gray AES, PSC; Fred Bentley, President & CEO, DexKo Global; Rebekah Gray, President & CEO, Gray Construction; Stephen Gray, President & CEO, Gray,
More news about: Gray Construction
Apr 14, 2026, 08:00 ET Palo Alto Networks Completes Acquisition of Koi to Secure the Agentic Endpoint
the completion of its acquisition of Koi. With this acquisition, Palo Alto Networks defines a new category of protection: Agentic Endpoint Security (AES). Koi's unique solution to securing vibe coding agents and autonomous endpoint tools comes as the industry reaches an inflection point of agentic adoption.The
More news about: Palo Alto Networks, Inc.
Apr 14, 2026, 06:30 ET INTEGRA ANNOUNCES RESULTS FROM NEAR-MINE OXIDE GOLD DRILLING AT FLORIDA CANYON, INCLUDING 138 METRES AT 0.32 G/T AU AND 128 METRES AT 0.36 G/T AU, HIGHLIGHTING NEAR-MINE GROWTH AND MINE LIFE EXTENSION POTENTIAL
(10 mesh) and pulverizing a 300 g split to >85% passing 75 microns.Gold analysis was performed on a 30-gram pulp using fire assay with ICP-AES finish. Samples returning >10 ppm Au were re-assayed using a gravimetric finish. Additionally, samples with Au >0.156 ppm underwent cyanide-soluble
More news about: Integra Resources Corp.
Apr 13, 2026, 06:00 ET IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
combination showed an early trend in improvement for OS versus ICTWell-tolerated, with manageable safety profile consistent with previously reported AEsNDA submission planned for H2'26 to support U.S. accelerated approval filing. Full data from OptimUM-02 to be presented at major medical conference
More news about: IDEAYA Biosciences, Inc.
Apr 10, 2026, 08:30 ET MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation
More news about: MetaVia Inc.
Apr 09, 2026, 09:50 ET eInfochips' EIC PROPEL™ Now Available in the Microsoft Marketplace
IoT devices through a single dashboard, with real-time telemetry and automation workflows.End-to-end security: Zero-trust design with AES-256 encryption, X.509 certificate-based authentication, and secure provisioning.Multitenant scalability: Isolation, governance, and policy-based
More news about: eInfochips
Apr 09, 2026, 08:00 ET Oracle AI Database Raises the Bar for Availability and Security Across Mission-Critical Workloads
computers become available. Oracle AI Database 26ai supports post-quantum readiness with NIST-approved quantum-resistant hybrid key exchange using TLS 1.3, AES-256 encryption for data protection, and quantum-safe public-key algorithms for authentication and digital signing.Database Security Central:
More news about: Oracle
Apr 08, 2026, 08:00 ET New Peer-Reviewed Research Demonstrates Effectiveness of Paradigm Health Study Conduct Products
Specialists in Babylon, NY, and Clearview Cancer Institute in Huntsville, AL. The clinical context for this study is collection of infusion-related AEs in patients with multiple myeloma who are treated with daratumumab.The authors piloted an EHR-integrated research platform designed to streamline
More news about: Paradigm Health, Inc.
Apr 07, 2026, 08:40 ET NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer's Disease
approach to treating Alzheimer's Disease."The primary objective of the study, safety and tolerability, was achieved, with overall Adverse Events (AEs) similar across the treatment and placebo groups. No treatment related Serious Adverse Events (SAEs) were reported in the active arm. Preliminary analysis
More news about: NeuroTherapia, Inc.
Apr 07, 2026, 02:00 ET Eluvio Announces Unified Platform for Zero-Copy Broadcast Distribution, D2C OTT Streaming & Monetization, and Inline AI Video Intelligence with Commercial Availability of Content Fabric "Bucharest Release"
contribution — extending to any sporting venue or remote location.End-to-End Security & Authorization: Multi-layer AES encryption with proxy re-encryption into per-session key spaces. Per-session authorization enforces availability windows, geo-restrictions, ACLs, and
More news about: Eluvio, Inc.
Apr 06, 2026, 08:00 ET Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression
events (AEs) were mild to moderate in severity. The most commonly related AEs observed across both active and placebo groups included injection site reactions, headache, and diarrhea, all of which were transient and resolvable. Notably, no subjects discontinued or withdrew from the study due to AEs or any
More news about: Alar Pharmaceuticals Inc.
Apr 06, 2026, 08:00 ET Oracle Appoints Hilary Maxson as Chief Financial Officer
in driving performance, scaling operations, and advancing the company's strategic transformation. Earlier in her career, Maxson spent 12 years at the AES Corporation, where she held senior leadership roles across finance, strategy, and M&A, supporting complex, capital-intensive infrastructure investments
More news about: Oracle Corporation
Apr 02, 2026, 08:00 ET Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
was associated with ~4 times higher odds of treatment discontinuation due to any adverse event (AEs) (odds ratio [OR] [95% CI]: 4.1 [1.3, 13.0]) and ~14 times higher odds of treatment discontinuation due to AEs related to gastrointestinal (GI) issues (OR [95% CI]: 13.9 [2.0, 96.0]).1Although
More news about: NOVO NORDISK INC.
Apr 02, 2026, 08:00 ET Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026
was associated with ~4 times higher odds of treatment discontinuation due to any adverse event (AEs) (odds ratio [OR] [95% CI]: 4.1 [1.3, 13.0]) and ~14 times higher odds of treatment discontinuation due to AEs related to gastrointestinal (GI) issues (OR [95% CI]: 13.9 [2.0, 96.0]).1Although
More news about: NOVO NORDISK INC.
Apr 01, 2026, 08:30 ET AES Announces Successful Completion of Consent Solicitation for its 2028 Notes
ARLINGTON, Va., April 1, 2026 /PRNewswire/ -- The AES Corporation (the "Company" or "AES") (NYSE: AES) today announced that it has received the requisite consents from registered holders of its 5.450% Senior Notes due 2028 (the
More news about: The AES Corporation
Apr 01, 2026, 08:30 ET IPALCO Enterprises, Inc. Announces Extension of Expiration Time for Previously Announced Consent Solicitations
Enterprises, Inc. is owned by The AES Corporation, a global power company, with CDP Infrastructures Fund L.P., a wholly owned subsidiary of La Caisse de dépôt et placement du Québec (CDPQ), as minority interest holder.About AESThe AES Corporation (NYSE: AES) is a Fortune 500 global energy
More news about: IPALCO Enterprises
Apr 01, 2026, 08:30 ET DPL LLC Announces Extension of Expiration Time for Previously Announced Consent Solicitation
respect of the proposed transaction between The AES Corporation ("AES") and Horizon Parent, L.P. ("Parent"). In connection with the proposed transaction, AES expects to file a proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC"). AES also may file other documents with the SEC
More news about: DPL LLC
Mar 30, 2026, 17:40 ET BTQ Technologies Provides Full-Year 2025 Corporate Update Highlighting Commercial Progress Across QCIM, QPerfect, QSSN and Bitcoin Quantum
with development boards expected to debut in Q3 2026. ASIC IP performance estimates are expected in Q2 2026 for ML-KEM, ML-DSA, SHA-3, and AES workloads. The Company's current roadmap contemplates silicon-proven ASIC IP availability in the first half of 2027 and secure element silicon
More news about: BTQ Technologies Corp.
Mar 30, 2026, 08:30 ET AES Announces Extension of Consent Solicitation for its 2028 Notes
ARLINGTON, Va., March 30, 2026 /PRNewswire/ -- The AES Corporation (the "Company" or "AES") (NYSE: AES) today announced that it has extended the expiration time for its previously announced solicitation of consents (the "Consent
More news about: The AES Corporation
Mar 30, 2026, 08:30 ET DPL LLC Announces Extension of Expiration Time for Previously Announced Consent Solicitation
respect of the proposed transaction between The AES Corporation ("AES") and Horizon Parent, L.P. ("Parent"). In connection with the proposed transaction, AES expects to file a proxy statement on Schedule 14A with the Securities and Exchange Commission ("SEC"). AES also may file other documents with the SEC
More news about: DPL LLC
Mar 30, 2026, 08:30 ET IPALCO Enterprises, Inc. Announces Extension of Expiration Time for Previously Announced Consent Solicitations
Enterprises, Inc. is owned by The AES Corporation, a global power company, with CDP Infrastructures Fund L.P., a wholly owned subsidiary of La Caisse de dépôt et placement du Québec (CDPQ), as minority interest holder.About AESThe AES Corporation (NYSE: AES) is a Fortune 500 global energy
More news about: IPALCO Enterprises
Mar 26, 2026, 11:54 ET Grid Scale Battery Market to Expand at 23% CAGR by 2031 Amid Renewable Integration and Grid Modernization Trends, Says a Mordor Intelligence Reports
TechnologyWartsilaPanasonicLG Energy SolutionSamsung SDIBYDEast Penn ManufacturingGS YuasaClariosAES CorporationPowin EnergyHitachi EnergyNEC Energy SolutionsEnerSysESS TechAmbriRedflowEnerVenueCheck
More news about: Mordor Intelligence Private Limited
Mar 26, 2026, 09:32 ET CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0
of Grade ≥3 Treatment-Related Adverse Events (TRAEs). No excessive toxicities related to CTLA-4 occurred, and the incidence of Grade ≥3 VEGF-related AEs was low.CS2009 monotherapy demonstrates potent antitumor activity in later-line "cold" tumors that are not sensitive to PD-(L)1 mAb. An overall
More news about: CStone Pharmaceuticals
Mar 26, 2026, 08:53 ET CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
toxicities that typically occurred in combination therapies containing CTLA-4 and PD-(L)1 were observed, and the incidence of Grade ≥3 VEGF-related AEs was low.Compelling Efficacy in Lung Cancer: CS2009 monotherapy demonstrates potentially transformative Phase I/II efficacy in Non-Small
More news about: CStone Pharmaceuticals